Results within specific high-risk groups
| . | 3-y CNS relapse rates, % . | Events/n . | HR* (95% CI) . | 3-y difference,% (EOT, intercalated) . |
|---|---|---|---|---|
| CNS IPI 4-6 | 9.1 (6.9-11.9) | 49/600 | ||
| Intercalated | 9.4 (6.5-13.5) | 28/337 | 1.00 | −0.7 (−4.4-5.4) |
| End of treatment | 8.6 (5.6-13.1) | 21/263 | 0.92 (0.52-1.62) | |
| CNS IPI 5-6 | 10.5 (5.9-16.0) | 21/210 | ||
| Intercalated | 11.8 (6.7-20.1) | 12/118 | 1.00 | −0.4 (−6.8-13.1) |
| End of treatment | 9.1 (4.6-17.4) | 9/92 | 0.96 (0.41-2.29) | |
| Testicular involvement | 7.5 (4.2-13.2) | 14/175 | ||
| Intercalated | 6.0 (2.3-15.3) | 8/80 | 1.00 | −0.4 (−4.0-9.3) |
| End of treatment | 8.5 (4.1-17.2) | 6/95 | 0.92 (0.32-2.68) | |
| Renal/adrenal involvement | 11.3 (7.6-16.7) | 25/240 | ||
| Intercalated | 14.4 (8.9-23.0) | 16/138 | 1.00 | −4.5 (−9.9-6.6) |
| End of treatment | 7.6 (3.7-15.5) | 9/102 | 0.67 (0.30-1.52) | |
| Breast involvement | 9.7 (3.6-24.6) | 5/56 | ||
| Intercalated | 5.3 (1.3-19.5) | 3/38 | 1.00 | 2.8 (−3.9-34.5) |
| End of treatment | 20.5 (5.6-60.3) | 2/18 | 1.56 (0.26-9.39) | |
| ≥3 extranodal sites | 7.6 (5.2-10.9) | 29/377 | ||
| Intercalated | 8.0 (5.0-12.8) | 16/215 | 1.00 | 0.0 (−4.1-8.1) |
| End of treatment | 7.1 (4.0-12.3) | 13/162 | 1.01 (0.48-2.10) | |
| Any high-risk factor above | 7.6 (5.9-9.7) | 65/885 | ||
| Intercalated | 7.4 (5.2-10.4) | 34/482 | 1.00 | 0.0 (−2.8-4.3) |
| End of treatment | 7.7 (5.3-11.1) | 31/403 | 1.00 (0.61-1.62) |
| . | 3-y CNS relapse rates, % . | Events/n . | HR* (95% CI) . | 3-y difference,% (EOT, intercalated) . |
|---|---|---|---|---|
| CNS IPI 4-6 | 9.1 (6.9-11.9) | 49/600 | ||
| Intercalated | 9.4 (6.5-13.5) | 28/337 | 1.00 | −0.7 (−4.4-5.4) |
| End of treatment | 8.6 (5.6-13.1) | 21/263 | 0.92 (0.52-1.62) | |
| CNS IPI 5-6 | 10.5 (5.9-16.0) | 21/210 | ||
| Intercalated | 11.8 (6.7-20.1) | 12/118 | 1.00 | −0.4 (−6.8-13.1) |
| End of treatment | 9.1 (4.6-17.4) | 9/92 | 0.96 (0.41-2.29) | |
| Testicular involvement | 7.5 (4.2-13.2) | 14/175 | ||
| Intercalated | 6.0 (2.3-15.3) | 8/80 | 1.00 | −0.4 (−4.0-9.3) |
| End of treatment | 8.5 (4.1-17.2) | 6/95 | 0.92 (0.32-2.68) | |
| Renal/adrenal involvement | 11.3 (7.6-16.7) | 25/240 | ||
| Intercalated | 14.4 (8.9-23.0) | 16/138 | 1.00 | −4.5 (−9.9-6.6) |
| End of treatment | 7.6 (3.7-15.5) | 9/102 | 0.67 (0.30-1.52) | |
| Breast involvement | 9.7 (3.6-24.6) | 5/56 | ||
| Intercalated | 5.3 (1.3-19.5) | 3/38 | 1.00 | 2.8 (−3.9-34.5) |
| End of treatment | 20.5 (5.6-60.3) | 2/18 | 1.56 (0.26-9.39) | |
| ≥3 extranodal sites | 7.6 (5.2-10.9) | 29/377 | ||
| Intercalated | 8.0 (5.0-12.8) | 16/215 | 1.00 | 0.0 (−4.1-8.1) |
| End of treatment | 7.1 (4.0-12.3) | 13/162 | 1.01 (0.48-2.10) | |
| Any high-risk factor above | 7.6 (5.9-9.7) | 65/885 | ||
| Intercalated | 7.4 (5.2-10.4) | 34/482 | 1.00 | 0.0 (−2.8-4.3) |
| End of treatment | 7.7 (5.3-11.1) | 31/403 | 1.00 (0.61-1.62) |
High risk CNS IPI: 9.5% (6.2-14.4) EOT and 9.4% (6.5-13.5) intercalated. High risk (all factors): 9.5% (6.6-13.5) EOT and 8.6% (5.9-12.4) intercalated.
CNS IPI, central nervous system international prognostic index; EOT, end of treatment; HR, hazard ratio.
EOT vs intercalated. Events post 3 years: 8 events (5 EOT and 3 intercalated). Five-year rates: EOT: 7.3% (5.2-10.1) and 6.5 (4.7-9.1) intercalated.